Hims Partners with Novo Nordisk While Lilly Launches Oral GLP-1
Two big moves just shook up the GLP-1 world: Hims is ditching compounded versions to team up with Novo Nordisk, while Eli Lilly quietly launched their first weight loss pill.
Hims Says Goodbye to Compounded GLP-1s
Here's something that'll affect a lot of people: Hims & Hers just announced they're partnering with Novo Nordisk to offer FDA-approved GLP-1 medications instead of the compounded versions they've been selling.
What does this actually mean for you? If you've been getting your semaglutide through Hims, you'll likely be switched from a compounded version to the real deal - think Ozempic or Wegovy instead of a pharmacy-mixed alternative.
The company's clearly trying to get ahead of regulatory pressure. Compounded medications have been under scrutiny lately, and this move puts them on much safer ground. Plus, with 2.5 million subscribers and $2.35 billion in revenue last year, they've got the clout to negotiate directly with big pharma now.
But let's be real - this probably means price changes are coming. FDA-approved versions typically cost more than compounded ones, though Hims might absorb some of that difference to keep customers happy.
Lilly's First Oral GLP-1 Pill Is Here
Meanwhile, Eli Lilly just launched Foundayo, and it's kind of a big deal - it's their first oral GLP-1 for weight loss. Until now, if you wanted Mounjaro or Zepbound, you had to deal with weekly injections.
So what's different about Foundayo? It's a daily pill instead of a shot, which sounds great until you dig into the details. Most oral GLP-1s come with their own set of rules - you might need to take it on an empty stomach, wait before eating, or deal with different side effects than the injectable versions.
Lilly's been pretty quiet about pricing and availability details, which usually means they're still figuring out how to position it against their existing products. The timing's interesting too - launching at a pharma conference in India suggests they might be testing international markets first.
What This Means for Your Options
Both of these changes point to the same thing: the GLP-1 market is maturing fast. Companies are moving away from the wild west days of compounded medications and racing to offer more convenient options.
For Hims customers, expect some communication about switching to FDA-approved versions over the next few months. Your medication might change names and possibly price, but the active ingredient should stay the same.
If you're interested in oral options, Foundayo joins the growing list of non-injectable GLP-1s, though we're still waiting on real-world availability and cost details.
Bottom Line: The GLP-1 landscape just got a bit more legitimate with Hims partnering with Novo Nordisk, and potentially more convenient with Lilly's new oral option. Keep an eye on your costs though - these moves toward "premium" versions usually come with premium prices.
